A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Status:
Completed
Trial end date:
2016-05-17
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out whether adding an experimental vaccine
called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve
progression free survival (slowing the growth of tumors) of patients with relapsed EGFRvIII
positive glioblastoma.